MTHFR C 677T mutation and 4G/5G PAI-1 polymorphism in patient with polycystic ovarian syndrome by Radaković, Branko & Šprem Goldštajn, Marina
Coll. Antropol. 31 (2007) 3: 919–921
Case report
MTHFR C 677T Mutation and 4G/5G PAI-1
Polymorphism in Patient With Polycystic
Ovarian Syndrome
Branko Radakovi} and Marina [prem Gold{tajn
Department for Gynecology and Obstetrics, School of Medicine, University of Zagreb, Zagreb, Croatia
A B S T R A C T
Combined oral contraceptives (Ocs) are the most commonly used androgen supresors and the treatment of choice for
menstrual dysfunction in women with polycystic ovarian syndrome (PCOs). Although OCs have remained popular due
to their convenience and effectiveness, there have been continuing concerns about adverse effects. The OCs have long been
known to incur and increased risk of venous thromboembolism especially in carriers of common inherited thrombo-
embolic defects. Factor V Leiden, prothrombin factor G20210A polymorphism, MTHFR (C677T) mutation and 4G/5G
polymorphism of the PAI-1 gene account for the majority of thromboembolic events in association with oral contraceptive
use. The aim of the article is to present woman with unrecognized inherited thrombophilia who was treated with OCs
due to PCOs signs.
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Introduction
Polycystic ovarian syndrome (PCOs) is the most com-
mon endocrinopathy in women. It is associated with both
reproductive and metabolic disorders1. The therapeutic ap-
proaches to PCOs include lifestyle modifications, di-
etary-induced weight loss, insulin-senziting agents, anti-
androgens and oral contraceptives (OCs), or by ovarian
drilling procedure2. Combined OCs are frequently used an-
drogen suppressors and the treatment of choice for men-
strual dysfunction in PCOs patients. Although OCs have
remained popular due to their convenience and effective-
ness, there have been continuing concerns about adverse
effects. The OCs has long been known to incur and in-
creased risk of venous thromboembolism (VTE)3. The great
problem in clinical practise is OCs-triggering of venous
thromboembolic events in carriers of common inherited
thromboembolic defects. Factor V Leiden, prothrombin fac-
tor G20210A polymorphism, methylene tetrahydrofolate
reductase (MTHFR-C677T) mutation and 4G/5G polymor-
phism of the PAI-1 gene account for the majority of
thromboembolic events, particularly in association with
oral contraceptive use4,5. The aim of the article is to present
woman with unrecognized inherited thrombophilia who
was treated with OCs due to PCOs signs.
Case Report
A 30-year nouliparous with polycystic ovarian syn-
drome was treated by her general practitioner with com-
bined oral contraceptive pills containing 35 mg of ethynil
estradiol and 2 mg of cyproterone acetate for six months.
She was admitted to the University Hospital Zagreb for
care due to dysfunctional uterine bleeding during OCs
use. Anamnestically, her mother died from cerebrovascu-
lar ischaemic stroke, and father has overcomed pulmo-
nary embolism episode. An internal examination and ul-
trasound scan of the pelvis were unremarkable. Accor-
ding to a positive family history of venous thrombosis she
was tested for eventually inherited coagulopathy. DNA
analysis for mutation in factor V Leiden, prothrombin
genes, MTHFR, 4G/5G PAI-1, F II 20210 A and FV R5
06Q was obtained. Plasma measurements of antithrom-
bin, protein C, protein S, total homocysteine levels, and
antiphospholipid antibodies were performed. Homozy-
gous MTHFR–C 677 T using real time PCR/LC-PCR,
hyperhomocysteinemia and 4G/5G PAI-1 polimorphysm
using PCR-SSCP were determined. Total homocysteine
plasma level was 25 mmol/L (5–15). F II 20210A (PCR)
and FV R 5 06Q (PCR) mutation was not found in
serume sample using PCR technique. Although the
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G20210A prothrombin mutation was not found, the pro-
thrombin levels measured by a chromogenic assay was
elevated (1.38, normal range 0.70–1.30) We found an in-
crease in levels of procoagulant factors VII, X and XII.
Antiphospholipide (LAC and anticardiolipin) antibodies
were negative. Plasma level of D-dimers was estimated
at 0.2 mg/L (normal range less than 0.3 mg/L). Plasma
level of protein C (78%, normal range 75–125), protein S
(65%, normal range 48–120) and antithrombin activity
95.8% (75–125) was within normal range.
Discussion
VTE events represent a serious complication related
to hormonal contraception3,6. Presence of inherited throm-
bophilia increases the risk for VTE due to oral contracep-
tive use up to an absolute risk of 3 per 1000 person-years,
in comparison with the baseline risk of 3 to 6 per 10 000
person-years7,8. The risk is further increased by first us-
age, the use of preparations containing third- generation
progestins, and thrombophilia due to antithrombin, pro-
tein C and S deficiency as well as homozygous factor V
(Leiden) and combined defects. The most likely mecha-
nism explaining the increased risk of VTE is the changes
provoked by the Ocs on the hemostatic and fibrinolytic
systems. There is an increase in levels of procoagulant
factors such as factors VII, X, XII and XIII associated
with estrogen use, as well as reductions in anticoagulant
factors including protein S and antithrombin5,6. There is
also an increase in fibrinolysis, which is thought to re-
flect a reduction in levels of PAI-1 combined with an in-
crease in plasminogen5,6. There is significant interaction
between the use of the oral contraceptive pill and herita-
ble thrombophilia. The best studied example is the inter-
action between factor V Leiden and OCs, showing that
the risk for VTE events was increased more than 30-fold
for women with factor V Leiden who used combined pill7.
Bloemenkamp et al. reported a 50-fold increased risk of
VTE for carriers of factor V Leiden using third genera-
tion OCs, compared with non-users without the factor V
mutation8. Legnani et al. found that elevated prothrom-
bin levels, even in women without G20210A prothrom-
bin mutation, are associated with an increased risk for
venous thromboembolism and that oral contraceptive
use potentiates such association9. Although the G20210A
prothrombin mutation was not found in our patient, the
prothrombin level measured by a chromogenic assay was
elevated what could display a strong interaction with
OCs use. Diamanti-Kandaraksi et al. concluded the PCOs
patients had significantly higher fre- quency of 4G/5G
and 4G/4G PAI-1 polymorphism10. Also, patients with
PCOs have higher levels of PAI-1. The presence of the 4G
allele in PAI-1 promoter region of the gene further in-
creases the PAI-1 levels. It is known that PAI-1 is a key
negative regulator of the fibrinolytic system. The PAI-1
gene 4G/5G polymorphism may modulate the inhibitor’s
synthesis thus influence PAI-1 expression and throm-
botic risk in patients with inherited thrombophilia11. The
odds ratio of bearing a mutation on the MTHFR gene is
1.2-fold higher in women with PCOs than in women
without PCOs12. Homozygous genotype of C677TMTHFR
mutation is associated with hyperhomocysteinaemia in
the presence of low folate concentration12,13. Prevalence
of homozygous persons in different races is 13.9%12. The
high frequency of the C677T mutation worldwide is sur-
prising if homozygotes have an increased risk of athero-
sclerosis and venous thrombosis. However, although a
range adverse events are associated with hyperhomo-
cysteinaemia it is unclear whether screening for this con-
dition should be added to the list of inherited throm-
bophilias likely to be associated with thrombosis. Oral
contraceptive pill use is associated with exponentially
higher VTE relative risks when used by women who
carry an inherited hypercoagulable state. According to
currently lack of reliable screening tools, we recom-
mended to avoid oral contraceptive use not only among
non-PCOs women, but also in PCOs patients with either
a personal history of VTE or a strong family history until
evaluated for hemostatic abnormalities, and perhaps lim-
iting the use of desogestrel or gestodene containing oral
contraceptives3,6. Women with PCOs and no inherited
thrombophilia seem to be able to follow hormonal ther-
apy without having increased risk for thromboembolic
complications when the same principles as in non-PCOs
women are applied14. However, inherited thrombophilia
could complicated treatment modalities in patients with
PCOs15. Therefore, other treatment modalities should be
considered for women with PCOs and inherited throm-
bophilia such as inzulin senziting agents, antiandrogens
or ovarian drilling procedure.
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MUTACIJA MTHFR C677T I 4G/5G PAI-1 POLIMORFIZAM U PACIJENTICE S
POLICISTI^NIM OVARIJSKIM SINDROMOM
S A @ E T A K
Kombinirani oralni kontraceptivi su naj~e{}e kori{teni supresori androgena, i lijek izbora u terapiji poreme}aja
menstruacijskog ciklusa u `ena s policisti~nim ovarijskim sindromom. Iako su kombinirani oralni kontraceptivi popu-
larni zbog prakti~nosti i u~inkovitosti, postoji kontinuirana zabrinutost zbog ne`eljenih u~inaka. Poznato je da kombi-
nirani oralni kontraceptivi poti~u i pove}avaju rizik nastanka venskog tromboembolizma, posebice u nositeljica nasljed-
nih tromboembolijskih defekata. Faktor V Leiden, polimorfizam protrombinskog faktora G20210A, mutacija MTHFR
(C677T) i polimorfizam 4G/5G PAI-1gena povezani su s ve}inom tromboembolijskih dogadjaja u `ena koje koriste oral-
nu hormonsku kontracepciju. Cilj ovog rada je prikazati `enu s neprepoznatom nasljednom trombofilijom, koja je lije~e-
na oralnim kontraceptivima zbog znakova policisti~nog ovarijskog sindroma.
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